InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases

INF904 is an orally administered, small molecule inhibitor of the C5a receptor that has shown antiinflammatory therapeutic effects in several pre-clinical disease models. Further, in contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that INF904 has minimal inhibition of the cytochrome P450 3A4/5 (CYP3A4/5) enzymes, which play an important role in the metabolism of a variety of metabolites and drugs, including glucocorticoids. Reported results from a first-in-human study demonstrated ...